A股異動 | 吉藥控股(300108.SZ)漲停 控股股東或將變更為本草匯醫藥
格隆匯11月13日丨吉藥控股(300108.SZ)漲停,報5.03元,最新總市值33.5億,換手率12%,現有封單36萬餘手。公司昨日公告稱,本草匯醫藥擬受讓公司控股股東及實控人盧忠奎出售的5%股份。同時,盧忠奎及黃克鳳擬將其合計持有的公司剩餘19.23%股份對應的表決權全權不可撤銷的委託本草匯醫藥行使。完成後,本草匯醫藥將合計享有公司24.23%表決權,公司的控股股東變更為本草匯醫藥,實際控制人變更為劉舒。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.